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LETTERS TO EDITOR 
discipline of medical profession) by the IPSs of 
the states, when compiled and edited would 
form an excellent reference work, and can be 
published. Such a reference work will also 
become a basis in future to argue that the post-
graduate students of every discipline need 2 to 
3 months' posting in psychiatry. 
I hope that the profession will rise to the 
occasion and achieve the desirable end result. 
C. SHAMASUNDAR, 250, 43 Cross, 9 Main, 5 Block, 
Jayanagar, Bangalore 560 041. 
HIGH DOSE FLUOXETINE IN OBSESSIVE 
COMPULSIVE DISORDER 
Sir, 
Fluoxetine has proven efficacy in treat-
ment of obsessive compulsive disorder (OCD). 
Double blind, randomized trials of fluoxetine 
using 20, 40 or 60 mg doses showed a dose 
response relationship with greater efficacy at 
60 mg/day dose (Montgomery et al., 1993; 
Tollefson et al., 1994). The maximum recom-
mended dose of fluoxetine in OCD is 80 mg/ 
day. In literature search I did not come across 
any report of use of more than 80 mg/day of 
fluoxetine. I hereby report two cases of OCD 
who showed good response to more than 80 
mg/day of fluoxetine with minimal adverse 
effects. 
Case I: A 40 year old, married male, diagnosed 
as a case of OCD (ICD-10). The chief symp-
toms were recurrent intrusive faces of persons 
known to him, repeated touching of objects in 
the room an performing rituals while walking 
on the'road. These symptoms were present for 
6 years. Because of severity of symptoms he 
was unable to carry out his work at home and 
office. He was given fluoxetine which was in-
creased up to 80 mg/day in four months. The 
improvement was 75% on this dose. The dose 
was further increased gradually in two months 
upto 100 mg/day. There was complete remis-
sion of symptoms. The adverse effects were 
mild anorexia, tremors in hand and occasional 
headache which decreased further with time. 
Case II : A 35 year old married male, shop-
keeper by occupation presented with symptoms 
of repeated checking of money while receiving 
and returning it back to the customer. Symp-
toms were affecting his work and was unable 
to run his shop properly. He was diagnosed as 
a case of OCD (ICD-10). He was given fluoxet 
ine to start with 20 mg/day and gradually in-
creased upto 90 mg/day in 6 months. On this 
dose he showed almost complete remission of 
symptoms. He continued to have mild anorexia, 
no other side effect was reported by him. 
Both of them are maintained on these 
doses ior last six months. In view of the above 
two cases, a conclusion may be drawn that 
persons suffering from OCD fluoxetine may be 
given at higher than 80 mg/day, as the improve-
ment is dose related, and side effect are mini-
mal, rather than switching to augmentation or 
other drugs once the maximum recommended 
dose of fluoxetine is reached. 
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BURDEN OF CARE IN PARENTS OF 
CHILDREN SUFFERING FROM HAEMA-
TOLOGICAL MALIGNANCIES 
Sir, 
We read with interest the above article 
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by Kulhara & colleagues in this Journal (Vol. 
40 1, 13-20, 1998). Close on the heels of the 
^ IPS presidential address, exhorting one and all 
to integrate our speciality with other branches 
of medicine it is indeed a welcome study. In the 
course of our consultation liaison work, we too 
have noted significant burden in families, where 
a child has chronic medical/surgical illness. 
Highlighting this as a necessary focus of man-
agement plans and facilitating such plans dq 
form a key role for child psychiatrists in the 
general hospital setting and we congratulate the 
authors on their effort. 
We, have certain comments on the study. 
A child psychiatric control would have placed 
the situation in some perspective. Regression 
analysis using the global burden scores (we 
appreciate that total burden is not possible with 
the instrument used) would have been interest-
ing. We are intrigued by the use of the FBS, an 
instrument which was basically devised to 
measure burden in families of patients with 
chronic mental illness. It would be useful to know 
the authors experience of using the FBS in this 
vastly different sample. Also information on 
number of other children in the families would 
have been of clinical value, as the families are 
faced with issues like death of the ailing 
children and so on. 
M. V. ASHOK, Asst. Professor, Dept. of Psy-
chiatry, VIJAYA RAMAN, Lecturer Clinical 
(Child) Psychology, St. John's Medical College 
Hospital, Bangalore. 
OR. PARMANAND KULHARA'S RESPONSE 
Sir, 
My response to the observations of 
Raman and Ashok are as follows : 
1. We are thankful to the writers for the encour-
aging comments about our paper. 
2. The point about a child psychiatric control is 
debatable because one is immediately faced 
with the problem of nature and the purpose of 
the control. 
3. It is acknowledged that the Family Burden 
Scale is an instrument which is basically 
designed to measure burden in a family with 
chronic mental illness. However, we in this 
department' have used this instrument success-
fully to measure burden in patients other than 
mental disorders and our present study on fam-
ily burden is one such explore. 
Our expertise suggests that there is 
nothing very specific psychiatric about the scale 
and if one is measuring burden then our exper-
tise shows that this scale can be used relatively 
easily in various disease category patients. 
PARMNAND KULHARA, M.D., F.R.C. Psych., 
M.A.M.S., Additional Professor & Head, 
PGIMER, Chandigarh 160012. 
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